Morrison & Foerster advises Santen Pharmaceutical Co., Ltd in $225 million share purchase agreement with Eyevance Pharmaceuticals Holdings Inc.

Morrison & Foerster advised Santen Pharmaceutical Co., Ltd., a company dedicated to ophthalmology, in its acquisition of Eyevance Pharmaceuticals Holdings Inc., a company that develops and commercializes topical ophthalmic products targeting the ocular surface and anterior segment, through Santen’s wholly owned U.S. subsidiary for $225 million.

The MoFo deal team is led by San Francisco corporate partner Jackie Liu, with additional support from corporate associates Michael G. Williams and James Lee, and technology transactions partner Masato Hayakawa.

Read Santen’s press release about the transaction: Santen and U.S. Ophthalmic Company Eyevance Enters into Share Purchase Agreement.